PDF(Pubmed)
Abstract：
UNASSIGNED: Hemangioblastoma (HB) is a rare and highly vascularized tumor that originates from the central nervous system as well as other part of the body. They can appear sporadically or as part of von Hippel-Lindau (VHL) disease, a rare hereditary cancer syndrome. Although surgery can cure the majority of HBs, the disease shows a treatment-refractory challenge upon recurrence. HBs express a high amount of vascular endothelial growth factor (VEGF) which is responsible for angiogenesis and subsequently tumor progression. Anti-angiogenic treatment like bevacizumab has showed effect on HB, so we hypothesized that anlotinib could trigger HB regression via its inhibitory effect on VEGF.
UNASSIGNED: We will share our experience in treating a 62-year-old woman with multiple recurrent lumbar and sacral cord HBs. She was treated with anlotinib (8mg qd d1-14, q3w) for three months and her follow up radiological examination demonstrated marked tumor regression which was evaluated as having partial response pursuant to RECIST 1.1 system. She is currently still receiving treatment of anlotinib orally and the lesions continuously reduced.
UNASSIGNED: We have reported that anlotinib can cause significant radiographic response in a patient with multiple recurrent lumbar and sacral cord HBs for the first time. This might enable a novel therapeutic approach for patients with multiple recurrent HB or those with multiple lesions such as in VHL disease which are difficult to resect surgically.
UNASSIGNED: We will share our experience in treating a 62-year-old woman with multiple recurrent lumbar and sacral cord HBs. She was treated with anlotinib (8mg qd d1-14, q3w) for three months and her follow up radiological examination demonstrated marked tumor regression which was evaluated as having partial response pursuant to RECIST 1.1 system. She is currently still receiving treatment of anlotinib orally and the lesions continuously reduced.
UNASSIGNED: We have reported that anlotinib can cause significant radiographic response in a patient with multiple recurrent lumbar and sacral cord HBs for the first time. This might enable a novel therapeutic approach for patients with multiple recurrent HB or those with multiple lesions such as in VHL disease which are difficult to resect surgically.
摘要：
未经证实：血管母细胞瘤（HB）是一种罕见且高度血管化的肿瘤，起源于中枢神经系统以及身体的其他部位。它们可以偶尔出现或作为vonHippel-Lindau（VHL）疾病的一部分，一种罕见的遗传性癌症综合症.虽然手术可以治愈大部分的HBs，该疾病在复发时显示出治疗难治性挑战。HBs表达高量的血管内皮生长因子(VEGF),其负责血管生成和随后的肿瘤进展。像贝伐单抗这样的抗血管生成治疗对HB有影响，因此,我们假设安洛替尼可以通过其对VEGF的抑制作用引发HB消退.
UNASSIGNED：我们将分享我们在治疗一名62岁女性多发性腰椎和骶索复发HBs方面的经验。她接受安洛替尼（8mgqdd1-14，q3w）治疗三个月，她的随访放射学检查显示出明显的肿瘤消退，根据RECIST1.1系统评估为具有部分反应。她目前仍在口服接受安洛替尼治疗，病变持续减少。
UNASSIGNED：我们首次报道了安洛替尼可在腰椎和骶索多次复发的患者中引起显着的影像学反应。这可能为患有多种复发性HB或患有多种病变的患者（例如VHL疾病）提供一种新的治疗方法，这些患者很难通过手术切除。
UNASSIGNED：我们将分享我们在治疗一名62岁女性多发性腰椎和骶索复发HBs方面的经验。她接受安洛替尼（8mgqdd1-14，q3w）治疗三个月，她的随访放射学检查显示出明显的肿瘤消退，根据RECIST1.1系统评估为具有部分反应。她目前仍在口服接受安洛替尼治疗，病变持续减少。
UNASSIGNED：我们首次报道了安洛替尼可在腰椎和骶索多次复发的患者中引起显着的影像学反应。这可能为患有多种复发性HB或患有多种病变的患者（例如VHL疾病）提供一种新的治疗方法，这些患者很难通过手术切除。
